Novavax CEO 接受金融时报采访时说 “I would love to hear more public support from the US government and I don’t know whether they’ve been too involved in some of the other vaccines or they’ve been too busy,” said Stan Erck, chief executive of Novavax, adding US authorisation for its jab could happen “within weeks”.” 目前全世界就剩美国，日本，南非等几国没批准了（不包括中俄朝）。 Novavax said its protein-based Covid-19 vaccine will be a strong competitor to the BioNTech/Pfizer and Moderna jabs despite its late arrival because of public concerns over the safety of its rivals’ messenger RNA technology. But the US biotech, which began shipping its vaccine to Europe and Asia in January following months of long delays because of regulatory challenges, has called on Washington to do more to promote its vaccine, which has still not been authorised by US regulators.
同一篇金融时报的文章中提到，主要就是他们家没法搞定大规模生产，而且mrna是在几亿人身上试验过的，novavax理论上更安全，但是也没有能力在实验中提供足够的数据作出证明，所以没有特别强的紧急性来批准，其实并没有那么多阴谋论的东西。 But the company has struggled to provide data to US regulators that demonstrate it can manufacture jabs in a consistent manner. However, Novavax has not done a head-to-head study pitting its jab against either the BioNTech/Pfizer or Moderna vaccines to provide accurate data comparing safety and adverse reactions.
目前全世界就剩美国，日本，南非等几国没批准了（不包括中俄朝）。
Novavax said its protein-based Covid-19 vaccine will be a strong competitor to the BioNTech/Pfizer and Moderna jabs despite its late arrival because of public concerns over the safety of its rivals’ messenger RNA technology. But the US biotech, which began shipping its vaccine to Europe and Asia in January following months of long delays because of regulatory challenges, has called on Washington to do more to promote its vaccine, which has still not been authorised by US regulators.
辉瑞都不招opt，对移民也不友好。
时机不一样，市场上已经有其他疫苗，现在的标准就高了。FDA一向如此。
而且它家最大问题是生产，自己搞不定生产，抱怨也没用。
同一篇金融时报的文章中提到，主要就是他们家没法搞定大规模生产，而且mrna是在几亿人身上试验过的，novavax理论上更安全，但是也没有能力在实验中提供足够的数据作出证明，所以没有特别强的紧急性来批准，其实并没有那么多阴谋论的东西。
But the company has struggled to provide data to US regulators that demonstrate it can manufacture jabs in a consistent manner.
However, Novavax has not done a head-to-head study pitting its jab against either the BioNTech/Pfizer or Moderna vaccines to provide accurate data comparing safety and adverse reactions.
pfizer可是连印度要做local trial的要求都不肯答应的
novavax除了美帝不批 其他批的国家也不少
别说FDA标准高，如果真高的话，也不会批准30%的药。
建议看一看《dopesick》，FDA官员的尽头是大药厂。
一定要去打哦